Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia

Véronique Leblond; Jean-Richard Eveillard; Driss Chaoui; Doriane Cavalieri; Caroline Dartigeas; Lise Willems; Ronan Le Calloch; Fathia Merabet; Xavier Roussel; Benoît Bareau; Sabine Tricot; Jehan Dupuis; Stéphanie Poulain; Kamel Laribi; Damien Roos‐Weil

doi:10.1038/s41375-025-02833-x

Affiliated Institutions

Related Publications

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Edward B. Garon , Matthew D. Hellmann , Naiyer A. Rizvi +15 more

PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We rep...

2019 Journal of Clinical Oncology 1115 citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann , D. Quietzsch , Frank Gieseler +17 more

Purpose To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic p...

2006 Journal of Clinical Oncology 682 citations

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Caroline Robert , Jean‐Jacques Grob , Daniil Stroyakovskiy +23 more

First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a <i>BR...

2019 New England Journal of Medicine 1283 citations

Long-Term Clinical Course of Patients After Termination of Ventricular Tachyarrhythmia by an Implanted Defibrillator

Arthur J. Moss , Henry Greenberg , Robert B. Case +7 more

Background— The implanted cardioverter defibrillator (ICD) improves survival in high-risk cardiac patients. This analysis from the MADIT-II trial database examines the long-term...

2004 Circulation 583 citations

Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

Yusuf Yazıcı , Tuulikki Sokka , Daniel Aletaha +2 more

The two major advances over the 1990s in the treatment of rheumatoid arthritis (RA) were a shift in strategy from a "pyramid", in which disease modifying anti-rheumatic drugs (D...

2004 PubMed 240 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Véronique Leblond, 
                                
                                    Jean-Richard Eveillard, 
                                
                                    Driss Chaoui
                                
                                et al.
                            
                            (2025). 
                            Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia. 
                            Leukemia
                            
                            .
                            https://doi.org/10.1038/s41375-025-02833-x

Identifiers

DOI: 10.1038/s41375-025-02833-x